IVA

Inventiva Sa

IVA.US inventivapharma.com
4.02
-0.12 (-2.90%)
USD · NASDAQ
52-week range
3.35
7.98
Trading at 14% of the 52-week range
Market Cap
949.61M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
-0.17
Div. Yield
N/A
% Institutions
41.80%
% Insiders
0.00%

1 Year

-30.3%

3 Year

+8.9%

10 Year

-70.0%
Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Company Information

Company Name
Inventiva Sa
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US46124U1079
CIK: 0001756594
Currency: USD
Full Time Employees: 69
Phone: 33 3 80 44 75 00
Fiscal Year End: December
IPO Date: Jul 10, 2020
Description:

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Address:

50 rue de Dijon, Daix, France, 21121

People

Directors & Officers

Name Title Year Born
Mr. Andrew Obenshain Chief Executive Officer 1974
Dr. Pierre Broqua Ph.D. Co-Founder 1962
Mr. Jean Volatier Executive VP Finance & Corporate Social Responsibility 1965
Dr. Martine Zimmermann Pharm.D. Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs 1969
Mr. Jason A. Campagna M.D., Ph.D. President of Research & Development and Chief Medical Officer 1966
Mr. Axel-Sven Malkomes Chief Financial Officer 1967
Mr. Christopher Benecchi Chief Operating Officer 1972
Ms. Susan Coles Chief Legal Officer 1966
Ms. Pamela Herbster Chief People Officer NA
Ms. Pascaline Clerc Ph.D. Executive Vice President of External and Corporate Affairs 1980

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Caligan Partners LP 8.16M Jun 30, 2026 3.46% $1.45 64.09%
Samsara BioCapital, LLC 6.31M Jun 30, 2026 2.67% $1.96 21.56%
Paradigm Biocapital Advisors LP 4.00M Jun 30, 2026 1.69% $0.28 0.00%
Andera Partners 3.63M Jun 30, 2026 1.54% $6.65 99.83%
Millennium Management LLC 3.51M Jun 30, 2026 1.49% $0.00 17.56%
Trails Edge Capital Partners, LP 2.66M Jun 30, 2026 1.13% $1.60 0.00%
Franklin Templeton Inc 2.46M Mar 31, 2026 1.04% $0.00 -1.54%
Squadron Capital Management LLC 2.44M Jun 30, 2026 1.03% $2.86 355.14%
SymBiosis Capital Partners, LLC 2.35M Mar 31, 2026 1.00% $24.76 -9.46%
UBS Group AG 2.32M Mar 31, 2026 0.98% $0.00 -12.29%
Aberdeen Group PLC 2.31M Jun 30, 2026 0.98% $0.01 0.00%
ADAR1 Capital Management LLC 2.17M Mar 31, 2026 0.92% $0.71 -19.76%
Polar Capital Holdings PLC 2.13M Mar 31, 2026 0.90% $0.04 6.67%
Patient Square Capital LP 1.97M Jun 30, 2026 0.83% $1.15 0.00%
NEXTBio Capital Management LP 1.79M Jun 30, 2026 0.76% $3.11 34.08%
Integral Health Asset Management, LLC 1.52M Jun 30, 2026 0.64% $0.23 280.00%
Yu Fan 1.50M Mar 31, 2026 0.64% $8.58 0.00%
BOOTHBAY FUND MANAGEMENT, LLC 1.47M Mar 31, 2026 0.62% $0.11 123.14%
NEA Management Company, LLC 1.46M Mar 31, 2026 0.62% $0.46 0.00%
Ikarian Capital, LLC 1.43M Mar 31, 2026 0.60% $0.64 184.34%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Franklin Biotechnology Discv A(acc)USD 1.93M 0.82% ▲ 15.32% Jul 31, 2026
2 abrdn World Healthcare 1.38M 0.58% ▲ 13.72% Jul 31, 2026
3 abrdn Life Sciences Investors 1.25M 0.53% ▲ 14.67% Jul 31, 2026
4 Franklin Biotechnology Discovery A 1.01M 0.43% ▲ 4.68% Jul 31, 2026
5 Fidelity Advisor Biotechnology I 685.40K 0.29% ▲ 0.00% Jul 31, 2026
6 Simplify Propel Opportunities ETF 313.48K 0.13% ▲ 0.00% Aug 31, 2026
7 Artisan Non-U.S. Small-Mid Growth Comp 144.29K 0.06% ▼ 26.29% Jun 30, 2026
8 Artisan International Small-Mid Investor 144.29K 0.06% ▼ 26.29% Jun 30, 2026
9 Strategic Advisers Fidelity US TtlStk 63.68K 0.03% ▲ 0.00% Jul 31, 2026
10 Fidelity Nasdaq Composite Index 39.42K 0.02% ▲ 14.75% Jul 31, 2026

Financial Highlights

Market Cap: $949.61M
EBITDA: $-132.50M
Book Value: $-0.17
Earnings/Share: $-2.21
Profit Margin: 0.00%
Operating Margin: -6,710.69%
ROA (TTM): -45.08%
ROE (TTM): -1,642.76%
Revenue (TTM): $6.76M
Revenue/Share (TTM): $0.04
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -89.90%

Valuation Metrics

Enterprise Value: $733.93M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 236.22M
Shares Float: 157.92M
% Insiders: 0.00%
% Institutions: 41.80%
Short % Float: 1.65%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$4.48M
Cost of Goods Sold
adjust
$-2.80M
Gross Profit
subtotal
$1.51M
SG&A
adjust
$-49.05M
R&D
adjust
$-83.61M
Other Operating Expense
adjust
$-4.71M
Operating Income
subtotal
$-130.95M
Other / Non-Operating Items
adjust
$-209.21M
Net Income
subtotal
$-340.16M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IVA.US!